Drug Information

Drug (ID: DG01781) and It's Reported Resistant Information

• Name: Bupivacaine
• Synonyms: Bupivacaine; 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide; 2180-92-9; DL-Bupivacaine; Marcaine; 38396-39-3; Bupivacaina; Anekain; Sensorcaine; Carbostesin; (+-)-Bupivacaine; Bupivacainum; 1-Butyl-2',6'-pipecoloxylidide; Exparel; Bupivacainum [INN-Latin]; Bupivacaina [INN-Spanish]; dl-1-Butyl-2',6'-pipecoloxylidide; 2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)-; 1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide; AH 250; Win 11318; Bloqueina; (+/-)-Bupivacaine; 2',6'-Pipecoloxylidide, 1-butyl-; 1-butyl-N-(2,6-dimethylphenyl)-piperidine-2-carboxamide; Marcain; C18H28N2O; SKY0402; CHEBI:77431; Xaracoll; LAC-43; cBupivacaine; Bupivacaine HCL KIT; Bucaine; bupivacaine base; (R)-Bupivacaine HCl; Bucaine (TN); DUR-843; EINECS 218-553-3; EINECS 253-911-2; 14252-80-3 (HCl); 73360-54-0 (HCl.H2O); Posimir; Bupivacaine [USAN:INN:BAN]; HSDB 7790; racemic bupivacaine; (RS)-bupivacaine; Bupivacaine liposome; SKY 0402; Exparel (TN); Liposomal bupivacaine; Bupivacaine-[13C]; Spectrum_001524; (1)-1-Butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide; Bupivacaine liposome injectable suspension; Prestwick0_000305; Prestwick1_000305; Prestwick2_000305; Prestwick3_000305; Spectrum2_001589; Spectrum3_000974; Spectrum4_001098; Spectrum5_001483; (.+/-.)-1-Butyl-2',6'-pipecoloxylidide; (.+/-.)-Bupivacaine; Bupivacaine (USAN/INN); LAC-43 (Salt/Mix); Epitope ID:122662; Marcaine spinal (Salt/Mix); CHEMBL1098; SCHEMBL25438; BSPBio_000270; BSPBio_002607; KBioGR_001516; KBioSS_002004; DivK1c_000758; SPBio_001558; SPBio_002489; BPBio1_000298; CHEBI:3215; GTPL2397; LIQ865; DTXSID2022703; KBio1_000758; KBio2_002004; KBio2_004572; KBio2_007140; KBio3_001827; LIQ-865; dl-1-Butyl-2,6-pipecoloxylidide; NINDS_000758; AH250; HMS2090F12; HMS3428P06; Marcaine hydrochloride (Salt/Mix); 1217442-06-2; 3-Ethyl-2-methylbenzoxazoliumiodide; BCP12242; BCP21825; HY-B0405; SKY-0402; 2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)-, (+-)-; AH-250; BDBM50350790; MFCD00243007; MFCD00941462; STL484283; AKOS001637202; AKOS016842516; AC-2096; BS-5224; CS-W023182; DB00297; MCULE-2286784276; IDI1_000758; NCGC00178579-01; NCGC00178579-02; BB166160; R962; SBI-0051846.P002; 18010-40-7 (HCl); DB-119016; AB00053674; FT-0623286; FT-0660567; FT-0699781; FT-0771900; C07529; D07552; J10217; Ropivacaine hydrochloride impurity, bupivacaine-; AB00053674-08; AB00053674-09; AB00053674_10; AB00053674_11; 180B929; A873847; L000695; Q422806; Q-100271; BRD-A01636364-003-05-2; BRD-A01636364-003-08-6; 1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboximidic acid; (plusmn)-1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide; 2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)-, (+/-)-; 2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)-, (.+/-.)-; 119427-31-5
• Indication:
  In total 2 Indication(s)
  Anaesthesia [ICD-11: 8E22]; Approved; [1]
  Pain [ICD-11: MG30]; Approved; [1]
• Drug Resistance Disease(s):
  Disease(s) with Resistance Information Discovered by Cell Line Test for This Drug (1 diseases)
  Neurotoxicity [ICD-11: NE61]; [1]
• Target: Voltage-gated sodium channel alpha Nav1.8 (SCN10A); SCNAA_HUMAN; [1]
• Formula: 5
• IsoSMILES: CCCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C
• InChI: InChI=1S/C18H28N2O/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21)
• InChIKey: LEBVLXFERQHONN-UHFFFAOYSA-N
• PubChem CID: 2474
• ChEBI ID: CHEBI:77431
• TTD Drug ID: D0A0FL

Type(s) of Resistant Mechanism of This Drug

  EADR: Epigenetic Alteration of DNA, RNA or Protein

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-22: Injury/poisoning/certain external causes consequences

Neurotoxicity [ICD-11: NE61]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: Metastasis associated lung adenocarcinoma transcript 1 (non-coding RNA) (Malat1) [1]

• Molecule Alteration: Up-regulation; Interaction
• Resistant Disease: Neurotoxicity [ICD-11: NE61.0]
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: SH-SY5Y cells; Abdomen; Homo sapiens (Human); CVCL_0019
• Experiment for Molecule Alteration: Western bloting analysis; Dual luciferase assay; Knockdown assay
• Experiment for Drug Resistance: CCK8 assay; Caspase-3 activity assay
• Mechanism Description: Knockdown of LncRNA MALAT1 alleviates bupivacaine-induced neurotoxicity via the miR-101-3p/PDCD4 axis.

References

• Ref 1: Knockdown of lncRNA MALAT1 alleviates bupivacaine-induced neurotoxicity via the miR-101-3p/PDCD4 axisLife Sci. 2019 Sep 1;232:116606. doi: 10.1016/j.lfs.2019.116606. Epub 2019 Jun 27.